Emilie Sbidian

Emilie Sbidian

Auto-generated profile, based on publicly available information

Emilie Sbidian

Epilogy Epidemiology and evaluation of therapeutics in dermatology and immune-mediated inflammatory diseases, Institut Mondor de Recherche Biomédicale, Inserm U955, Université Paris Est Créteil (UPEC), Créteil Cedex, France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
ESEmilie Sbidian
Emilie Sbidian
ACAnna Chaimani
Anna Chaimani
IGIgnacio Garcia-Doval
Ignacio Garcia-Doval
LDLiz Doney
Liz Doney
CDCorinna Dressler
Corinna Dressler
LCLaurence Le Cleach
Laurence Le Cleach

5 October 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
LHLéa HOISNARD
Léa HOISNARD
LVLaura Pina Vegas
Laura Pina Vegas
RDRosemay Dray-Spira
Rosemay Dray-Spira
AWAlain Weill
Alain Weill
MZMahmoud Zureik
Mahmoud Zureik
ESEmilie Sbidian
Emilie Sbidian
Objectives To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib and baricitinib) versus adalimumab in a large real-world population of patients with rheumatoid arthritis. Methods We conducted a nationwide population-based cohort study of the French national health data system, the exposed group initiating a JAKi and non-exposed group initiating adalimumab. We included all individuals who had their first dispensation of a JAKi or adalimumab between 1 July 2017 and 31 May 2021 and had rheumatoid arthritis. The primary endpoints were the occurrence of a MACE or VTE. Weighted hazard ratio (HRw) values were estimated with the inverse probability of treatment weighting method to account for confounding factors with concomitant administration of methotrexate as a time-varying variable. Results The cohort included 15 835 patients: 8481 and 7354 in the exposed and non-exposed groups (mean age 59.3 and 55.3 years, female 78.3% and 71.2%, respectively). During follow-up, 54 and 35 MACEs and 75 and 32 VTEs occurred in the exposed and non-exposed groups, respectively. Risk of MACEs for the exposed versus non-exposed group was not significant: HRw 1.0 (95% CI 0.7 to 1.5) (p=0.99), nor was risk of VTEs significant: HRw 1.1 (0.7 to 1.6) (p=0.63). Despite a lack of power, results were consistent among patients aged 65 years or older with at least one cardiovascular risk factor. Conclusions This study provides reassuring data regarding the risks of MACEs and VTEs in patients initiating a JAKi versus adalimumab, including patients at high risk of cardiovascular diseases.

12 July 2023 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
ESEmilie Sbidian
Emilie Sbidian
ACAnna Chaimani
Anna Chaimani
RGRobin Guelimi
Robin Guelimi
IGIgnacio Garcia-Doval
Ignacio Garcia-Doval
CHCamille Hua
Camille Hua
LCLaurence Le Cleach
Laurence Le Cleach

3 March 2021 in Hypertension
Verified
Journal Article
Open access
PDF file
LSLaura Semenzato
Laura Semenzato
JBJérémie Botton
Jérémie Botton
JDJérôme Drouin
Jérôme Drouin
BBBérangère Baricault
Bérangère Baricault
CVClémentine Vabre
Clémentine Vabre
MZMahmoud Zureik
Mahmoud Zureik
After initially hypothesizing a positive relationship between use of renin-angiotensin-aldosterone system inhibitors and risk of coronavirus disease 2019 (COVID-19), more recent evidence suggests negative associations. We examined whether COVID-19 risk differs according to antihypertensive drug class in patients treated by ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers (ARBs) compared with calcium channel blockers (CCBs). Three exclusive cohorts of prevalent ACE inhibitors, ARB and CCB users, aged 18 to 80 years, from the French National Health Insurance databases were followed from February 15, 2020 to June 7, 2020. We excluded patients with a history of diabetes, known cardiovascular disease, chronic renal failure, or chronic respiratory disease during the previous 5 years, to only consider patients treated for uncomplicated hypertension and to limit indication bias. The primary end point was time to hospitalization for COVID-19. The secondary end point was time to intubation/death during a hospital stay for COVID-19. In a population of almost 2 million hypertensive patients (ACE inhibitors: 566 023; ARB: 958 227; CCB: 358 306) followed for 16 weeks, 2338 were hospitalized and 526 died or were intubated for COVID-19. ACE inhibitors and ARBs were associated with a lower risk of COVID-19 hospitalization compared with CCBs (hazard ratio, 0.74 [95% CI, 0.65–0.83] and 0.84 [0.76–0.93], respectively) and a lower risk of intubation/death. Risks were slightly lower for ACE inhibitor users than for ARB users. This large observational study may suggest a lower COVID-19 risk in hypertensive patients treated over a long period with ACE inhibitors or ARBs compared with CCBs. These results, if confirmed, tend to contradict previous hypotheses and raise new hypotheses.

21 July 2021 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
LPLaetitia Penso
Laetitia Penso
RDRosemary Dray-Spira
Rosemary Dray-Spira
AWAlain Weill
Alain Weill
LVLaura Pina Vegas
Laura Pina Vegas
MZMahmoud Zureik
Mahmoud Zureik
ESEmilie Sbidian
Emilie Sbidian
Systemic nonbiologic therapies, targeted therapies, or biologics are commonly used to manage moderate to severe psoriasis, with higher efficacy for biologic than nonbiologic agents.1,2 With the fast emergence of these new therapeutic agents, evaluating long-term comparative safety in a real-world setting is needed because patients with moderate to severe psoriasis may be at increased risk of serious infection, depending on the biologic agent used.3

20 August 2016 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
HMHenri Montaudié
Henri Montaudié
CCC. Chiaverini
C. Chiaverini
ESE. Sbidian
E. Sbidian
ACA. Charlesworth
A. Charlesworth
JLJ-P. Lacour
J-P. Lacour
Inherited epidermolysis bullosa (EB) comprises a highly heterogeneous group of rare diseases characterized by exacerbated skin and/or mucosal fragility and blister formation after minor mechanical trauma. Level of cleavage in the skin, clinical features with immunofluorescence antigen mapping and/or electron microscopy examination of a skin biopsy and/or gene involved, type(s) of mutation present and sometimes specific mutation(s), allow to define the EB type and subtype. This family of genodermatoses exposes patients to several complications, cutaneous squamous cell carcinoma (cSCC) being the most severe of them. The aim of this systematic review was to document patients with EB who developed cSCC. A systematic literature search was performed, from inception to March 2014, using Medline, Embase, Cochrane and ClinicalTrials.gov databases. Only articles published in English and French were selected. The diagnosis of EB had to be confirmed by EM and/or IFM and/or mutation analysis, while cSCC had to be confirmed by histological analysis. Of 167 references in the original search, 69 relevant articles were identified, representing 117 cases. cSCCs were identified in all types of EB, though predominantly in recessive dystrophic EB (RDEB) forms (81 cases (69.2 %)). The median age at diagnosis was 36 years old (interquartile range (IQR), 27-48 years and range, 6-71 years) for all forms. Of those with measurements in the literature (88 cases (75.2 %)), tumor size was greater than 2 centimeters in 52 cases (59.1 %). The histopathological characteristics were specified in 88 cases (75.2 %) and well-differentiated forms predominated (73.9 %). No conclusion could be drawn on the choice of surgical treatment or the management in advanced forms. This study was retrospective and statistical analysis was not included due to various biases. This study design did not allow to infer prevalence, nor EB subtype risk for cSCC occurrence. Our study correlated with historical data shows that most of the cSCCs occurred in subjects with the RDEB subtype, however reports also show that cSCCs can present in any patients with EB. The first signs of cSCC developed at a younger age in EB patients than in non-EB patients. Interestingly, the cSCC duration, before its diagnosis, was shorter in individuals with RDEB than with junctional EB (JEB) and dominant dystrophic EB (DDEB). This study further emphasizes the importance of regular monitoring of EB patients, particularly with the RDEB subtype as they developed cSCC at a younger age.